The National Institute for Health and Care Excellence (NICE) has today published final draft guidance recommending a new treatment for people with diabetic macular oedema (DMO). DMO is the most common ...

Exonate Ltd. (the Company), an mRNA therapy company focused on treatments for diabetic complications, today announced its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a ...

Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein ...

March 26, 2007 – New York, NY -- The Juvenile Diabetes Research Foundation, the world’s largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in ...

Joseph M. Coney, MD, FACS, reviews best practices for improving adherence to treatment among patients with diabetic macular edema through comprehensive education on the disease and available therapies ...

For people living with diabetes, vision complications require immediate attention. Diabetic macular edema (DME), a condition causing fluid buildup in the eye’s central retina, demands particular ...

CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...

Justine R. Smith receives funding from Macular Disease Foundation Australia, Queensland Eye Institute Foundation, Flinders Foundation and the National Health and Medical Research Council of Australia.

(RTTNews) - Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial. The SPECTRA trial is ...

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for people with diabetic macular oedema (DMO) with thousands of people set to benefit from the ...